Clinical Trial: Efficacy and Safety of Infliximab Biosimilar in Treatment of Resistant Hidradenitis Suppurativa
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition: Hidradenitis Suppurativa
Study Type: Interventional
Official Title: Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa
Brief Summary:
The aim of this clinical trial is to assess the efficacy and safety of Infliximab biosimilar in patients of resistant Hidradenitis suppurativa. The main question it aims to answer are:how effective is infliximab biosimilar in treating resistant Hidradentis suppurativaIs infliximab biosimilar safe in these patients Patients will receive weekly injections of Infliximab Biosimilar Remsima, according to weight, for first 4 weeks, and then fortnightly for next 10 weeks. Patients will be followed up for 10 weeks post…
Read more